Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

E Choi, Boris Lacarra, Muhammed O. Afolabi, Boni Maxime Ale, Frank Baiden, Christine Bétard, Julie Foster, Benjamin Hamzé, Christine Schwimmer, Daniela Manno, Éric D’Ortenzio, David Ishola, Cheick Mohamed Keita, Babajide Keshinro, Yusupha Njie, Wim van Dijck, Auguste Gaddah, Dickson Anumendem, Brett Lowe, Renaud Vatrinet, Bolarinde Lawal, Godfrey T Otieno, Mohamed Samai, Gibrilla F. Deen, Ibrahim Swaray, A Kamara, Michael Kamara, Mame Aminata Diagne, Dickens Kowuor, Chelsea McLean, Bailah Leigh, Abdoul Habib Béavogui, Maarten Leyssen, Kerstin Lühn, Cynthia Robinson, Macaya Douoguih, Brian Greenwood, Rodolphe Thiébaut, Deborah Watson‐Jones, Thomas A. Mooney, Lansana Conteh, M A Bangura, H Jalloh, Ibrahim Franklyn Kamara, S Koroma, Mohamed Sesay, A T Deen, E L Kamara, Senesie Kamara, Alusine H. Koroma, I S Mansaray, Massah Massaquoi, A Nabie, Lazarus Odeny, Mahmud Sheku, Abdulai Jalloh, Amadou Sow, E Swaray, F Mansaray, T Sessie, J-hc Sunders, Samuel Turay, J Weekes, M Pessima, Alie Wurie, M Conteh, M I Jalloh, P. Kamara, D P Kanneh, M Kanneh, I Komeh, Mohamed Koroma, M Kuyateh, Tom Sesay, Peter Piot, Shelley Lees, Heidi J. Larson, Farba Faye, Daniel Tindanbil, Foday Morovia, J A KallonThe Lancet Global Health 2023 · DOI

TL;DR

This study evaluated the safety and immune response of a two-dose Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) in infants aged 4-11 months in Guinea and Sierra Leone. The vaccine was found to be safe and well-tolerated, inducing strong antibody responses, suggesting it could be a valuable tool for protecting this vulnerable population against Ebola virus disease.

What Problem Does This Paper Address?

Ebola virus disease (EVD) remains a significant global health threat, with outbreaks disproportionately affecting West and Central Africa. Infants and young children are particularly vulnerable, experiencing higher mortality rates and rapid disease progression. While effective Ebola vaccines exist for older populations, there was a critical gap in understanding their safety and immunogenicity in infants under one year old. This study directly addresses this gap by being the first to evaluate a specific two-dose Ebola vaccine regimen (Ad26.ZEBOV followed by MVA-BN-Filo) in this age group.

Methods

This was a phase 2, randomized, double-blind, active-controlled trial conducted at two sites in West Africa. Healthy infants aged 4-11 months were randomly assigned to receive either the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen or a meningococcal quadrivalent conjugate vaccine (MenACWY) as an active control. The primary objective was to assess safety and reactogenicity (local and systemic adverse events), while the secondary objective was to measure immunogenicity through EBOV glycoprotein-binding antibody concentrations. Infants were followed for up to a year, with antibody levels measured at key time points.

Datasets

Not applicable. This paper describes a clinical trial and does not use pre-existing datasets for training or evaluation.

Key Insights and Ideas

  • First-in-infant data: This study provides crucial, novel data on the safety and immunogenicity of an Ebola vaccine regimen in infants, a population previously underrepresented in clinical trials.
  • Comparable safety profile: The safety profile in infants was similar to that observed in older children and adolescents, indicating the vaccine is generally well-tolerated across pediatric age groups.
  • Robust immune response: The vaccine regimen elicited a strong and consistent antibody response in 100% of infants 21 days after the second dose, demonstrating its effectiveness in generating humoral immunity.
  • Age-related antibody levels: A notable finding was that antibody levels were numerically higher in infants compared to older children and adolescents, suggesting a potentially stronger immune response in younger individuals, though the reasons are not fully understood.
  • Geographical variation: Antibody levels showed some variation between Guinea and Sierra Leone, highlighting the importance of considering regional factors in vaccine response.

Key Results

  • Safety: The Ad26.ZEBOV and MVA-BN-Filo regimen was well-tolerated in infants. The most common solicited local adverse event was injection-site pain, and the most common systemic adverse events were irritability, decreased appetite, pyrexia, and decreased activity. No serious adverse events were found to be vaccine-related.
  • Immunogenicity:
    • At 21 days post-dose 2, the geometric mean concentration (GMC) of EBOV glycoprotein-binding antibodies was 27,700 ELISA units (EU)/mL in infants aged 4-8 months and 20,481 EU/mL in infants aged 9-11 months.
  • The responder rate was 100% (74 of 74 responded) in the Ebola vaccine group.
  • Antibody levels persisted, with 93% of younger and 100% of older infants still considered responders 12 months post-dose 1.
  • Control Group: The control group (MenACWY) showed minimal antibody responses to EBOV glycoprotein, as expected.

Limitations and Future Work

The authors acknowledge several limitations:

  • No efficacy data: The study did not assess clinical vaccine efficacy against EVD, and a correlate of protection has not yet been established. While the vaccine has shown protection in non-human primates, direct human efficacy data in infants is still needed.
  • Unknown reasons for age-related antibody differences: The higher antibody titers observed in infants compared to older age groups warrant further investigation to understand the underlying mechanisms.
  • Geographical variation: The observed differences in antibody levels between Guinea and Sierra Leone require further research to identify contributing factors, such as pathogen burdens, micronutrient status, or immune system activation.

Future work should focus on establishing correlates of protection and conducting efficacy trials to confirm the protective benefit of this vaccine regimen in infants against EVD. Further research into the factors influencing the observed age- and geographically-related differences in immunogenicity is also recommended.

Summary updated

Abstract

For the French translation of the abstract see Supplementary Materials section.
BibTeX
@inproceedings{choi2023safety,
  author = {E Choi and Boris Lacarra and Muhammed O. Afolabi and Boni Maxime Ale and Frank Baiden and Christine Bétard and Julie Foster and Benjamin Hamzé and Christine Schwimmer and Daniela Manno and Éric D’Ortenzio and David Ishola and Cheick Mohamed Keita and Babajide Keshinro and Yusupha Njie and Wim van Dijck and Auguste Gaddah and Dickson Anumendem and Brett Lowe and Renaud Vatrinet and Bolarinde Lawal and Godfrey T Otieno and Mohamed Samai and Gibrilla F. Deen and Ibrahim Swaray and A Kamara and Michael Kamara and Mame Aminata Diagne and Dickens Kowuor and Chelsea McLean and Bailah Leigh and Abdoul Habib Béavogui and Maarten Leyssen and Kerstin Lühn and Cynthia Robinson and Macaya Douoguih and Brian Greenwood and Rodolphe Thiébaut and Deborah Watson‐Jones and Thomas A. Mooney and Lansana Conteh and M A Bangura and M A Bangura and H Jalloh and Ibrahim Franklyn Kamara and M Kamara and S Koroma and Mohamed Sesay and Mohamed Sesay and A T Deen and A Kamara and E L Kamara and Senesie Kamara and Alusine H. Koroma and I S Mansaray and Massah Massaquoi and A Nabie and Dickens Kowuor and Yusupha Njie and Lazarus Odeny and Mahmud Sheku and Abdulai Jalloh and Amadou Sow and E Swaray and F Mansaray and T Sessie and J-HC Sunders and Samuel Turay and J Weekes and M Pessima and Alie Wurie and M Conteh and M I Jalloh and P. Kamara and D P Kanneh and M Kanneh and I Komeh and Mohamed Koroma and M Kuyateh and F F Mansaray and Bailah Leigh and Deborah Watson‐Jones and Mohamed Samai and Gibrilla F. Deen and Tom Sesay and Peter Piot and Brian Greenwood and Shelley Lees and Heidi J. Larson and Muhammed O. Afolabi and David Ishola and Frank Baiden and Farba Faye and Daniel Tindanbil and Michael Kamara and Ibrahim Swaray and A Bangura and A M Kamara and Foday Morovia and J A Kallon},
  title = {{Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone}},
  booktitle = {The Lancet Global Health},
  year = {2023},
  doi = {10.1016/s2214-109x(23)00410-2},
}
Figure